StockNews.com assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research note published on Sunday. The firm issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Performance
Nabriva Therapeutics has a 1-year low of $1.22 and a 1-year high of $8.45. The stock has a market cap of $45.46 million, a PE ratio of -0.07 and a beta of 1.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85.
About Nabriva Therapeutics
Featured Articles
- Five stocks we like better than Nabriva Therapeutics
- Following Congress Stock Trades
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- Why Invest in High-Yield Dividend Stocks?
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- Where Do I Find 52-Week Highs and Lows?
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.